Werewolf Therapeutics Clinical Trial Data
Werewolf Therapeutics announced new clinical data from its Phase 1/1b trial of WTX-124 and Phase 1b/2 trial of WTX-330 for the treatment of solid tumors at the SITC 2026 Annual Meeting. WTX-124 demonstrated durable antitumor activity, including a complete response in a patient with cutaneous squamous cell carcinoma, and the company aligned with the FDA on a recommended Phase 2 dose of 18 mg. WTX-330 was reported as well-tolerated with evidence of monotherapy clinical activity in advanced, treatment-refractory disease.